Humacyte (HUMA) Cash from Operations (2020 - 2026)

Humacyte (HUMA) has 7 years of Cash from Operations data on file, last reported at 25104000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 25104000.0, up 12.22% year-over-year; the trailing twelve-month figure through Mar 2026 was 101504000.0 (down 2.17% YoY), and the FY2025 annual result was 105000000.0, down 7.03% from the prior year.
• Cash from Operations improved to 25104000.0 in Q1 2026 per HUMA's latest filing, from 26082000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 13100000.0 in Q3 2023 and troughed at 28600000.0 in Q1 2025.
• A 5-year average of 21919882.35 and a median of 22559000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations surged 45.09% in 2022, then sank 74.86% in 2024.
• A 5-year view of Cash from Operations shows it stood at 18959000.0 in 2022, then fell by 0.24% to 19005000.0 in 2023, then tumbled by 39.73% to 26555000.0 in 2024, then grew by 1.78% to 26082000.0 in 2025, then climbed by 3.75% to 25104000.0 in 2026.
• Business Quant data shows HUMA's Cash from Operations at 25104000.0 in Q1 2026, 26082000.0 in Q4 2025, and 23904000.0 in Q3 2025.